| Bioactivity | Pdpe 1.3 is a peptide inhibitor, The main activity is to destroy the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). By interfering with this interaction, PDpep1.3 restores the degradation function of the endocytosomes and lysosomes, thereby reducing alpha-synuclein levels and protecting dopaminergic neurons from alpha-synuclein mediated degradation. Pdpe 1.3 can be used in the study of neurodegenerative diseases and protein-protein interactions[1]. |
| Sequence | Asp-Glu-Glu-Ile-Glu-Arg-Gln-Leu-Lys-Ala-Leu-Gly |
| Shortening | DEEIERQLKALG |
| Formula | C59H101N17O22 |
| Molar Mass | 1400.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Nim S, et al. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease[J]. Nature Communications, 2023, 14(1): 2150. |